Application

BASILEA

Basilea Pharmaceutica International AG, Allschwil

Trademark/Service Mark Application, Principal Register

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97876573
Filing Date: 04/06/2023

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 97876573
MARK INFORMATION
*MARK \\TICRS\EXPORT18\IMAGEOUT 18\978\765\97876573\xml1 \ APP0002.JPG
SPECIAL FORM YES
USPTO-GENERATED IMAGE NO
LITERAL ELEMENT BASILEA
COLOR MARK NO
*DESCRIPTION OF THE MARK
(and Color Location, if applicable)
The mark consists of the word "BASILEA" surrounded by an oval.
PIXEL COUNT ACCEPTABLE YES
PIXEL COUNT 711 x 250
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK Basilea Pharmaceutica International AG, Allschwil
*MAILING ADDRESS Hegenheimermattweg 167b
*CITY Allschwil
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY Switzerland
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
4123
*EMAIL ADDRESS XXXX
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION Switzerland
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 001 
*IDENTIFICATION Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions and for the treatment of infections and diseases; chemical substances for use in research and development of pharmaceuticals for the treatment of dermatological conditions and for the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
FILING BASIS SECTION 1(b)
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
FILING BASIS SECTION 1(b)
INTERNATIONAL CLASS 042 
*IDENTIFICATION Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations
FILING BASIS SECTION 1(b)
ATTORNEY INFORMATION
NAME Evan A. Raynes
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME Symbus Law Group PLLC
STREET 1775 I Street, NW, Suite 1150
CITY Washington
STATE District of Columbia
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP/POSTAL CODE 20006
PHONE 202-258-0652
EMAIL ADDRESS eraynes@symbus.com
OTHER APPOINTED ATTORNEY Symbus Law Group PLLC
CORRESPONDENCE INFORMATION
NAME Evan A. Raynes
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE eraynes@symbus.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) trademarks@symbus.com; uspto@dockettrak.com
FEE INFORMATION
APPLICATION FILING OPTION TEAS Standard
NUMBER OF CLASSES 3
APPLICATION FOR REGISTRATION PER CLASS 350
*TOTAL FEES DUE 1050
*TOTAL FEES PAID 1050
SIGNATURE INFORMATION
SIGNATURE /Evan A. Raynes/
SIGNATORY'S NAME Evan A. Raynes
SIGNATORY'S POSITION Attorney of record, DC bar member
SIGNATORY'S PHONE NUMBER 202-258-0652
DATE SIGNED 04/06/2023
SIGNATURE METHOD Signed directly within the form



PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Trademark/Service Mark Application, Principal Register

Serial Number: 97876573
Filing Date: 04/06/2023

To the Commissioner for Trademarks:

MARK: BASILEA (stylized and/or with design, see mark)
The literal element of the mark consists of BASILEA. The applicant is not claiming color as a feature of the mark. The mark consists of the word "BASILEA" surrounded by an oval.
The applicant, Basilea Pharmaceutica International AG, Allschwil, a corporation of Switzerland, having an address of
      Hegenheimermattweg 167b
      Allschwil 4123
      Switzerland
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 001:  Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions and for the treatment of infections and diseases; chemical substances for use in research and development of pharmaceuticals for the treatment of dermatological conditions and for the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 005:  Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.




The owner's/holder's proposed attorney information: Evan A. Raynes. Other appointed attorneys are Symbus Law Group PLLC. Evan A. Raynes of Symbus Law Group PLLC, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      1775 I Street, NW, Suite 1150
      Washington, District of Columbia 20006
      United States
      202-258-0652(phone)
      eraynes@symbus.com

Evan A. Raynes submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:
      Evan A. Raynes
       PRIMARY EMAIL FOR CORRESPONDENCE: eraynes@symbus.com
       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@symbus.com; uspto@dockettrak.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $1050 has been submitted with the application, representing payment for 3 class(es).

Declaration

Declaration Signature

Signature: /Evan A. Raynes/   Date: 04/06/2023
Signatory's Name: Evan A. Raynes
Signatory's Position: Attorney of record, DC bar member
Signatory's Phone Number: 202-258-0652
Signature method: Signed directly within the form
Payment Sale Number: 97876573
Payment Accounting Date: 04/06/2023

Serial Number: 97876573
Internet Transmission Date: Thu Apr 06 17:45:05 ET 2023
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XX-2023040617450743
0500-97876573-86061895471919cf52b64c2252
f1287a6b8beae468d80c7a9b7bf6de45f1374d05
8-CC-45056636-20230406172834630340

Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed